Central Pacific Bank Trust Division Lowers Stock Holdings in Sanofi (NASDAQ:SNY)

Central Pacific Bank Trust Division cut its holdings in Sanofi (NASDAQ:SNY) by 1.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,750 shares of the company’s stock after selling 450 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Sanofi were worth $1,242,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new stake in Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners raised its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. Sunbelt Securities Inc. boosted its stake in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in shares of Sanofi during the second quarter worth $51,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Down 0.2 %

NASDAQ:SNY traded down $0.10 on Friday, hitting $48.09. The stock had a trading volume of 943,362 shares, compared to its average volume of 1,090,078. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The stock has a market cap of $122.04 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 1.23 and a beta of 0.58. The company has a fifty day moving average price of $49.26 and a two-hundred day moving average price of $52.00. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. During the same quarter last year, the firm posted $2.55 earnings per share. Sanofi’s revenue was up 12.3% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.06 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.